Purchase this article with an account.
N. Restrepo, L. Wu, J. G. Sanchez, M. Maia, M. J. Saravia, J. Arevalo, for the Pan-American Collaborative Retina Study Group; Comparison of 2 Doses of Intravitreal Bevacizumab (Avastin) for Proliferative Diabetic Retinopathy: Results From the Pan-American Collaborative Retina Study Group (PACORES) at 24-Month Follow-Up. Invest. Ophthalmol. Vis. Sci. 2010;51(13):4233.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To compare the effects of two doses (1.25 vs 2.5 mg) of intravitreal bevacizumab (Avastin) on retinal neovascularization (RN) in patients with proliferative diabetic retinopathy (PDR)
In this interventional, retrospective, multicenter study, we reviewed the clinical records of 39 consecutive patients (43 eyes) with RN due to PDR with a mean age of 54 ± 12.5 years and a follow-up of 24 months. Patients were treated with at least 1 intravitreal injection of 1.25 mg or 2.5 mg of bevacizumab (IVB). Patients underwent ETDRS BCVA testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and follow-up visits
The mean number of IVB injections per eye was 3.6 ± 1.6 (range: 1 to 7 injections). Twenty-four (55.8%) eyes received IVB at a dose of 1.25 mg, and 19 (44.2%) eyes received a dose of 2.5 mg. Thirty-one eyes (72.1%) had previous panretinal photocoagulation (PRP). In the 1.25 mg group, 8 eyes (33.3%) showed total regression of NVE and 6 eyes (25%) showed total regression of NVD, 5 (20.8%) showed partial regression of NVE and 5 eyes (20.8%) showed partial regression of NVD, and 9 eyes (37.5%) showed no regression of NVE and 13 eyes (54.2%) showed no regression of NVD. In the 2.5 mg group, 7 eyes (36.8%) showed total regression of NVE and 7 eyes (36.8%) showed total regression of NVD, 5 (26.3%) showed partial regression of NVE and 9 eyes (47.4%) showed partial regression of NVD, and 3 eyes (15.8%) showed no regression of NVE and 3 eyes (15.8%) showed no regression of NVD. Comparing the two groups, the difference was not statistically significant considering the number of eyes, which showed NVE regression (P = 0.09) and was statistically significant considering NVD regression (P = 0.005) in favor of the 2.5 mg group
IVB at doses of 1.25 mg or 2.5 provides total or partial regression of RN associated to PDR in 67.2% of eyes with improvement in BCVA and OCT. There was a statistically significant difference in eyes with more regression of NVD with the 2.5mg dose. No tachyphylaxis was identified at 24 months
This PDF is available to Subscribers Only